Fibrinogenolysis
Fibrinogenolysis is the biochemical process involving the breakdown of fibrinogen, a soluble plasma protein that is critical to blood clotting. This process is an essential component of the coagulation cascade, which helps to stop bleeding and initiate wound healing. Fibrinogenolysis is mediated by various enzymes, including plasmin and certain serine proteases, which cleave fibrinogen into smaller fragments. These fragments are unable to participate in the formation of a fibrin clot, thus regulating the clotting process and preventing excessive thrombosis.
Mechanism[edit | edit source]
The primary enzyme involved in fibrinogenolysis is plasmin. Plasmin is generated from its inactive precursor, plasminogen, through the action of activators such as tissue plasminogen activator (tPA) and urokinase. Once activated, plasmin cleaves fibrinogen, as well as fibrin, leading to the degradation of blood clots. This process is tightly regulated by various inhibitors, including alpha-2 antiplasmin and plasminogen activator inhibitor-1 (PAI-1), to prevent excessive bleeding.
Clinical Significance[edit | edit source]
Fibrinogenolysis plays a significant role in several clinical conditions. Enhanced fibrinogenolysis can lead to a reduction in fibrinogen levels, known as hypofibrinogenemia, which can increase the risk of bleeding. This condition may be observed in patients with disseminated intravascular coagulation (DIC), severe infections, or those receiving certain thrombolytic therapies.
Conversely, impaired fibrinogenolysis, due to excessive inhibitors or deficient plasmin activity, can contribute to thrombosis, the formation of harmful blood clots. Conditions such as deep vein thrombosis (DVT) and pulmonary embolism (PE) may result from such an imbalance.
Diagnosis and Treatment[edit | edit source]
Diagnosing disorders of fibrinogenolysis involves measuring the levels of fibrinogen and its degradation products in the blood, alongside other coagulation tests. Treatment depends on the underlying cause and may include the administration of anticoagulants to prevent clot formation or fibrinolytic agents to enhance clot breakdown.
See Also[edit | edit source]
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
